Research article summary (published 30 Oct 2009):

Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.

Full Abstract

BACKGROUND: Dutasteride is commonly used in patients that are also at risk for prostate cancer (PCa). Therefore, the influence of dutasteride on PCa markers has to be studied. To date, only the effect of dutasteride on serum prostate-specific antigen (PSA) has been studied. This was the first study to investigate the effect of dutasteride on the new PCa marker PCA3, longitudinally and in a dose dependent manner. METHODS: From April 25, 2005 to October 31, 2006, 16 subjects with benign prostatic hyperplasia (BPH) and 9 subjects with clinically localized PCa were enrolled at the urological outpatient clinics of one university hospital and one community hospital. Eight subjects with BPH and five with PCa received 0.5 mg dutasteride once daily for 3 months, eight with BPH and four with PCa received 3.5 mg. No subjects were withdrawn because of adverse effects. RESULTS: In all four groups both 0.5 and 3.5 mg dutasteride had a variable effect on the PCA3 score. In contrast, its other effects were consistent as it rapidly reduced serum DHT by >or=90%, over time increased serum T by 20-30%, over time halved serum PSA and decreased prostate volume by 10-16%. CONCLUSIONS: In this exploratory/pilot study the effect of dutasteride on the PCA3 score was variable. This should be taken into account while using PCA3 in diagnostics. As this study was exploratory, the influence of androgen-deprivation therapy on the PCA3 score should be analyzed further.

Author information

Author/s: van Gils, Martijn P M Q (MP); Hessels, Daphne (D); Peelen, W Pim (WP); Vergunst, Henk (H); Mulders, Peter F A (PF); Schalken, Jack A (JA);

Affiliation: Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

Journal and publication information

Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal: The Prostate (Prostate), published in United States. (Language: eng)

Reference: 2009-Nov; vol 69 (issue 15) : pp 1624-34

Dates: Created 2009/09/28; Completed 2009/10/15;

PMID: 19588525, status: MEDLINE (last retrieval date: 10/15/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Antigens, Neoplasm - biosynthesis; genetics; urine Azasteroids - adverse effects; therapeutic use Dihydrotestosterone - blood Dose-Response Relationship, Drug Enzyme Inhibitors - adverse effects; therapeutic use Humans Longitudinal Studies Male Middle Aged

Pilot Projects Prostate-Specific Antigen - blood Prostatic Hyperplasia - drug therapy; pathology; urine Prostatic Neoplasms - drug therapy; pathology; urine RNA, Messenger - biosynthesis; genetics Reverse Transcriptase Polymerase Chain Reaction Testosterone - blood Testosterone 5-alpha-Reductase - antagonists & inhibitors Tumor Markers, Biological - genetics; urine

Associated Chemicals: Antigens, Neoplasm (0) ; Azasteroids (0) ; Enzyme Inhibitors (0) ; RNA, Messenger (0) ; Tumor Markers, Biological (0) ; dutasteride (0) ; prostate cancer antigen 3, human (0) ; Dihydrotestosterone (521-18-6) ; Testosterone (58-22-0) ; Testosterone 5-alpha-Reductase (EC 1.3.99.5) ; Prostate-Specific Antigen (EC 3.4.21.77)

Related articles

These are the highest related articles currently in the database:

• Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. 29 Sep 2004
• Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. 29 Sep 2004
• Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. 30 Mar 2004
• [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia] 30 Aug 2002
• The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study. 30 Oct 2006
• Efficacy and tolerability of the dual 5alpha-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men. 17 Sep 2006
• Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group. 30 Dec 1992
• Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study. 30 Dec 1992
• The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. 20 Oct 1992
• Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. 30 Aug 2002

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.